Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP687383.RAC-tGh4R2aoENXWDR6hpdSbtNz5WyVephA9n3zzZkcDY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP687383.RAC-tGh4R2aoENXWDR6hpdSbtNz5WyVephA9n3zzZkcDY130_assertion type Assertion NP687383.RAC-tGh4R2aoENXWDR6hpdSbtNz5WyVephA9n3zzZkcDY130_head.
- NP687383.RAC-tGh4R2aoENXWDR6hpdSbtNz5WyVephA9n3zzZkcDY130_assertion description "[A phase II trial is ongoing to test the hypothesis that a compound, high-dose medroxyprogesterone acetate (MPA), used as an unconventional gluocorticoid, will stimulate breast cancer cells to reexpress Nm23-H1 and limit subsequent metastatic colonization.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP687383.RAC-tGh4R2aoENXWDR6hpdSbtNz5WyVephA9n3zzZkcDY130_provenance.
- NP687383.RAC-tGh4R2aoENXWDR6hpdSbtNz5WyVephA9n3zzZkcDY130_assertion evidence source_evidence_literature NP687383.RAC-tGh4R2aoENXWDR6hpdSbtNz5WyVephA9n3zzZkcDY130_provenance.
- NP687383.RAC-tGh4R2aoENXWDR6hpdSbtNz5WyVephA9n3zzZkcDY130_assertion SIO_000772 18698018 NP687383.RAC-tGh4R2aoENXWDR6hpdSbtNz5WyVephA9n3zzZkcDY130_provenance.
- NP687383.RAC-tGh4R2aoENXWDR6hpdSbtNz5WyVephA9n3zzZkcDY130_assertion wasDerivedFrom befree-2016 NP687383.RAC-tGh4R2aoENXWDR6hpdSbtNz5WyVephA9n3zzZkcDY130_provenance.
- NP687383.RAC-tGh4R2aoENXWDR6hpdSbtNz5WyVephA9n3zzZkcDY130_assertion wasGeneratedBy ECO_0000203 NP687383.RAC-tGh4R2aoENXWDR6hpdSbtNz5WyVephA9n3zzZkcDY130_provenance.